Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Q3 2025 value amounting to $27.8 million.

  • Ironwood Pharmaceuticals' Deferred Taxes rose 26156.75% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.7 million, marking a year-over-year increase of 4346.65%. This contributed to the annual value of $68.1 million for FY2024, which is 625.99% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Deferred Taxes stood at $27.8 million, which was up 26156.75% from $14.1 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Deferred Taxes high stood at $41.1 million for Q4 2024, and its period low was $670000.0 during Q1 2025.
  • Moreover, its 5-year median value for Deferred Taxes was $14.3 million (2023), whereas its average is $14.9 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Deferred Taxes skyrocketed by 94133.47% in 2022 and then tumbled by 8892.56% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Deferred Taxes (Quarter) stood at $1.9 million in 2021, then skyrocketed by 941.33% to $20.1 million in 2022, then skyrocketed by 55.6% to $31.3 million in 2023, then surged by 31.23% to $41.1 million in 2024, then tumbled by 32.43% to $27.8 million in 2025.
  • Its last three reported values are $27.8 million in Q3 2025, $14.1 million for Q2 2025, and $670000.0 during Q1 2025.